Login to Your Account



Aiming for Comeback, Intercell Hopes to Pad Coffers with $52M

By Nuala Moran
Staff Writer

Wednesday, May 9, 2012
LONDON – Intercell AG is raising €40 million (US$52 million) in debt and equity as it continues work to repair the damage wreaked by the clinical failure of vaccines against traveler's diarrhea and Staphylococcus aureus.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription